Roots Analysis

Protein-based biologics include the major and fastest growing class of pharmaceutical products. At present, the majority of human biologics are produced in mammalian and microbial cell cultures. Biologics produced in cell cultures necessitate capital-intensive facilities, fermenters, affluent downstream processing, cold storage and transportation, and sterile delivery approaches. These limitations encourage the development of alternative production systems. Currently, a large number of plant-based proteins are being assessed in clinical phases of development, including vaccine candidates against COVID 19 and multiple rare therapeutic disorders. Plant expression platforms offer features beyond the traditional advantages, and eukaryotic protein modification. The method has a vast number of advantages like, increased safety, low manufacturing cost, flexibility and speed, host engineering, and oral delivery of drugs. Novel transient expression vectors have been established that allow the...

 Females constitute 49.6% of the world’s total population and, in one of its reports, the US department of labor reported that females use digital health care solutions more than men. Further, in a recent survey, it was founded that the percentage of women adopting tele health platform rose from 13% to 38% post the outbreak of COVID-19. At present, there are more than 100 marketed solutions focused on women’s digital health market ; these contain applications, software, and devices. Some of these solutions have also been approved by the USFDA for therapeutic applications in areas, such as reproductive health and menstrual health.  It is worth noting that, NC° Birth Control, established by Natural Cycles, was the first application to receive approval from US FDA in 2018; the application can be used as a method of contraception and helps in regularly tracking menstrual cycle. Several developers are vigorously engaged in the development of solutions related to women’s digital hea...

Targeted protein degradation is an emergent modality that allows access to difficult-to-treat diseases. While traditional medicines such as small molecule inhibitors and monoclonal antibodies address fewer than 20% of the proteome, targeted degradation offers an exceptional means to tap into the rest of the vast, unexplored proteome. Through this, a disease can be addressed by controlling the amount of a harmful protein rather than trying to modulate or inhibit its function. The control of protein levels is accomplished with a small molecule drug called a protein degrader. Other Types Of Targeted Protein Degraders Currently, there are several other types of targeted protein degraders and molecular glues , which have been / are being developed for the treatment of a variety of clinical conditions, including acute myeloid leukemia, Alzheimer's disease, breast cancer, myelofibrosis, multiple myeloma, Parkinson's disease, prostate cancer, psoriasis, rheumatoid arthritis, and...